Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated:  4/14/2016
Washington University
mi
from
Saint Louis, MO
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated: 4/14/2016
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated:  4/14/2016
Multiple Sclerosis Center of North Eastern New York
mi
from
Latham, NY
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated: 4/14/2016
Multiple Sclerosis Center of North Eastern New York
mi
from
Latham, NY
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated:  4/14/2016
OMRF Multiple Sclerosis Center of Excellence
mi
from
Oklahoma City, OK
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated: 4/14/2016
OMRF Multiple Sclerosis Center of Excellence
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated:  4/14/2016
Swedish Medical Center
mi
from
Seattle, WA
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated: 4/14/2016
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated:  4/14/2016
Raleigh Neurology Associates PA
mi
from
Raleigh, CA
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated: 4/14/2016
Raleigh Neurology Associates PA
mi
from
Raleigh, CA
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated:  4/14/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated: 4/14/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated:  4/14/2016
London Health Sciences Centre
mi
from
London,
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Status: Enrolling
Updated: 4/14/2016
London Health Sciences Centre
mi
from
London,
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Cullman, AL
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Cullman, AL
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Pheonix, AZ
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Pheonix, AZ
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
San Diego, CA
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Bradenton, FL
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Orlando, FL
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Tampa, FL
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Tampa, FL
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
West Palm Beach, FL
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Lexington, KY
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
New Bedford, MA
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
New Bedford, MA
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Detroit, MI
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Chesterfield, MO
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Rochester, NY
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Charlotte, NC
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Columbus, OH
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Charlotte, SC
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Charlotte, SC
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Roanoke, VA
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Roanoke, VA
Click here to add this to my saved trials
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  4/14/2016
mi
from
Pleven,
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 4/14/2016
mi
from
Pleven,
Click here to add this to my saved trials
Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells
Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells
Status: Enrolling
Updated:  4/20/2016
Rutgers-RWJMS
mi
from
New Brunswick, NJ
Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells
Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells
Status: Enrolling
Updated: 4/20/2016
Rutgers-RWJMS
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE
Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE
Status: Enrolling
Updated:  5/10/2016
University at Buffalo Neurosurgery
mi
from
Buffalo, NY
Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE
Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE
Status: Enrolling
Updated: 5/10/2016
University at Buffalo Neurosurgery
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study of Electrical Impedance Myography (EIM) in ALS
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance
Status: Enrolling
Updated:  5/10/2016
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Study of Electrical Impedance Myography (EIM) in ALS
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance
Status: Enrolling
Updated: 5/10/2016
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Electrical Impedance Myography (EIM) in ALS
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance
Status: Enrolling
Updated:  5/10/2016
University of Miami Miller School of Medicine
mi
from
Miami, FL
Study of Electrical Impedance Myography (EIM) in ALS
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance
Status: Enrolling
Updated: 5/10/2016
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Study of Electrical Impedance Myography (EIM) in ALS
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance
Status: Enrolling
Updated:  5/10/2016
Massachusetts General Hospital
mi
from
Boston, MA
Study of Electrical Impedance Myography (EIM) in ALS
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance
Status: Enrolling
Updated: 5/10/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Electrical Impedance Myography (EIM) in ALS
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance
Status: Enrolling
Updated:  5/10/2016
Skulpt, Inc
mi
from
Boston, MA
Study of Electrical Impedance Myography (EIM) in ALS
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance
Status: Enrolling
Updated: 5/10/2016
Skulpt, Inc
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Electrical Impedance Myography (EIM) in ALS
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance
Status: Enrolling
Updated:  5/10/2016
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Study of Electrical Impedance Myography (EIM) in ALS
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance
Status: Enrolling
Updated: 5/10/2016
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of Electrical Impedance Myography (EIM) in ALS
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance
Status: Enrolling
Updated:  5/10/2016
SUNY Upstate Medical University
mi
from
Syracuse, NY
Study of Electrical Impedance Myography (EIM) in ALS
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance
Status: Enrolling
Updated: 5/10/2016
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  5/11/2016
Clinical Research Facility
mi
from
Mountlake Terrace, WA
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 5/11/2016
Clinical Research Facility
mi
from
Mountlake Terrace, WA
Click here to add this to my saved trials
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  5/11/2016
mi
from
Liege,
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 5/11/2016
mi
from
Liege,
Click here to add this to my saved trials
Locomotor Training in Persons With Multiple Sclerosis
Robotic Locomotor Training in Persons With Multiple Sclerosis
Status: Enrolling
Updated:  7/1/2016
UCLA
mi
from
Los Angeles, CA
Locomotor Training in Persons With Multiple Sclerosis
Robotic Locomotor Training in Persons With Multiple Sclerosis
Status: Enrolling
Updated: 7/1/2016
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Examining the Effects of a Telehealth Self-management Intervention in Multiple Sclerosis
Examining the Effects of Physical Activity Promotion, Fatigue Management Education, and Social Support Using a Telehealth Intervention Approach Among Adults With Multiple Sclerosis
Status: Enrolling
Updated:  7/12/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Examining the Effects of a Telehealth Self-management Intervention in Multiple Sclerosis
Examining the Effects of Physical Activity Promotion, Fatigue Management Education, and Social Support Using a Telehealth Intervention Approach Among Adults With Multiple Sclerosis
Status: Enrolling
Updated: 7/12/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Barrow Neurological Institute
mi
from
Phoenix, AZ
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
George Washington University Medical Faculty Associates
mi
from
Washington,
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
George Washington University Medical Faculty Associates
mi
from
Washington,
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Neurological Associates
mi
from
Ft. Lauderdale, FL
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Neurological Associates
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Neurology & Headache Specialist of Atlanta, L.L.C.
mi
from
Decatur, GA
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Neurology & Headache Specialist of Atlanta, L.L.C.
mi
from
Decatur, GA
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Radiant Research Alexian Brothers
mi
from
Elk Grove Village, IL
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Radiant Research Alexian Brothers
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Consultants in Neurology, Ltd.
mi
from
Northbrook, IL
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Consultants in Neurology, Ltd.
mi
from
Northbrook, IL
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Advanced Neurology Specialists
mi
from
Great Falls, MT
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Advanced Neurology Specialists
mi
from
Great Falls, MT
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Neurological Associates, P.C.
mi
from
Lincoln, NE
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Neurological Associates, P.C.
mi
from
Lincoln, NE
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Upstate Clinical Research, LLC
mi
from
Albany, NY
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Upstate Clinical Research, LLC
mi
from
Albany, NY
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
DENT Neurologic Group L.L.P.
mi
from
Amherst, NY
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
DENT Neurologic Group L.L.P.
mi
from
Amherst, NY
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Hospital for Joint Diseases - MS Care Center
mi
from
New York, NY
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Hospital for Joint Diseases - MS Care Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Institute For Human Performance
mi
from
Syracuse, NY
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Institute For Human Performance
mi
from
Syracuse, NY
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Raleigh Neurology Associates
mi
from
Raleigh, NC
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Raleigh Neurology Associates
mi
from
Raleigh, NC
Click here to add this to my saved trials